MX360699B - Derivados de espiro [2.4] heptano puenteado substituidos por piperazina, utilizados como agonistas del receptor alx. - Google Patents

Derivados de espiro [2.4] heptano puenteado substituidos por piperazina, utilizados como agonistas del receptor alx.

Info

Publication number
MX360699B
MX360699B MX2016000731A MX2016000731A MX360699B MX 360699 B MX360699 B MX 360699B MX 2016000731 A MX2016000731 A MX 2016000731A MX 2016000731 A MX2016000731 A MX 2016000731A MX 360699 B MX360699 B MX 360699B
Authority
MX
Mexico
Prior art keywords
receptor agonists
substituted bridged
piperazine substituted
bridged spiro
heptane derivatives
Prior art date
Application number
MX2016000731A
Other languages
English (en)
Other versions
MX2016000731A (es
Inventor
Corminboeuf Olivier
Pozzi Davide
Cren Sylvaine
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2016000731A publication Critical patent/MX2016000731A/es
Publication of MX360699B publication Critical patent/MX360699B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un derivado de espiro[2.4] heptano puenteado, substituido por piperazina de la fórmula (I), su preparación y su utilización como compuesto farmacéuticamente activo.
MX2016000731A 2013-07-18 2014-07-17 Derivados de espiro [2.4] heptano puenteado substituidos por piperazina, utilizados como agonistas del receptor alx. MX360699B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2013055906 2013-07-18
PCT/EP2014/065351 WO2015007830A1 (en) 2013-07-18 2014-07-17 Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists

Publications (2)

Publication Number Publication Date
MX2016000731A MX2016000731A (es) 2016-04-13
MX360699B true MX360699B (es) 2018-11-14

Family

ID=51205401

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000731A MX360699B (es) 2013-07-18 2014-07-17 Derivados de espiro [2.4] heptano puenteado substituidos por piperazina, utilizados como agonistas del receptor alx.

Country Status (13)

Country Link
US (1) US9533964B2 (es)
EP (1) EP3022188B1 (es)
JP (1) JP6330038B2 (es)
KR (1) KR20160033747A (es)
CN (1) CN105377824B (es)
AU (1) AU2014292064B2 (es)
BR (1) BR112016001106A8 (es)
CA (1) CA2915757A1 (es)
ES (1) ES2639798T3 (es)
MX (1) MX360699B (es)
RU (1) RU2016105310A (es)
TW (1) TW201536289A (es)
WO (1) WO2015007830A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3022188B1 (en) 2013-07-18 2017-06-07 Actelion Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
BR112016025659B1 (pt) 2014-05-13 2023-03-07 Novartis Ag Indutores de condrogênese, seu uso, e composição farmacêutica
ES2791340T3 (es) 2015-05-27 2020-11-03 Kyorin Seiyaku Kk Derivado de urea o sal farmacológicamente aceptable del mismo
CN107849049B (zh) 2015-05-27 2021-03-16 杏林制药株式会社 脲衍生物或其药用盐

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686454A (en) 1993-07-16 1997-11-11 Merck & Co., Inc. Camphorcarbonyl
WO2001057074A1 (en) 2000-02-04 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection
US20050164305A1 (en) 2002-04-03 2005-07-28 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
AU2004290368A1 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, FPRL1, as a tool for identifying compounds effective in the treatment of pain and inflammation
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
ATE520689T1 (de) 2007-12-18 2011-09-15 Actelion Pharmaceuticals Ltd Aminotriazolderivate als alx-agonisten
WO2010134014A1 (en) * 2009-05-18 2010-11-25 Actelion Pharmaceuticals Ltd Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists
NZ597453A (en) 2009-06-09 2013-03-28 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives as alxr agonists
US8674111B2 (en) 2009-06-12 2014-03-18 Actelion Pharmaceuticals Ltd. Oxazole and thiazole derivatives as ALX receptor agonists
EP2585054A1 (en) * 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
ES2553635T3 (es) * 2010-11-17 2015-12-10 Actelion Pharmaceuticals Ltd. Derivados de éster spiro[2.4]heptano puenteados
AR084172A1 (es) 2010-12-07 2013-04-24 Actelion Pharmaceuticals Ltd Derivados aminotriazol hidroxilados como agonistas del receptor alx
AR084173A1 (es) 2010-12-07 2013-04-24 Actelion Pharmaceuticals Ltd Derivados oxazolil-metileter como agonistas del receptor alx
WO2013009543A1 (en) 2011-07-11 2013-01-17 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
MA37618B1 (fr) * 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CN104284887B (zh) * 2012-05-16 2016-06-22 埃科特莱茵药品有限公司 作为alx受体激动剂的经1-(对-甲苯基)环丙基取代的桥联螺[2.4]庚烷衍生物
CA2898301C (en) 2013-03-06 2021-11-16 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
CN105007908B (zh) 2013-03-06 2017-10-03 阿勒根公司 用于治疗皮肤病的甲酰基肽受体2的激动剂的用途
EP3022188B1 (en) 2013-07-18 2017-06-07 Actelion Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx

Also Published As

Publication number Publication date
AU2014292064A1 (en) 2016-03-03
MX2016000731A (es) 2016-04-13
RU2016105310A (ru) 2017-08-23
BR112016001106A2 (es) 2017-07-25
US9533964B2 (en) 2017-01-03
EP3022188B1 (en) 2017-06-07
BR112016001106A8 (pt) 2017-12-26
CN105377824B (zh) 2017-08-04
EP3022188A1 (en) 2016-05-25
KR20160033747A (ko) 2016-03-28
TW201536289A (zh) 2015-10-01
JP6330038B2 (ja) 2018-05-23
AU2014292064B2 (en) 2018-07-05
US20160152584A1 (en) 2016-06-02
CA2915757A1 (en) 2015-01-22
JP2016525107A (ja) 2016-08-22
ES2639798T3 (es) 2017-10-30
WO2015007830A1 (en) 2015-01-22
CN105377824A (zh) 2016-03-02

Similar Documents

Publication Publication Date Title
NZ747259A (en) Soluble c5ar antagonists
PH12015501363A1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
NZ716840A (en) Combination formulation of two antiviral compounds
PH12015502013A1 (en) Pharmaceutical composition of s-ketamine hydrochloride
PH12015501957A1 (en) Pharmaceutical composition of s-ketamine hydrochloride
PH12014502465A1 (en) Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
MA40170A (fr) Dérivés hétérocycliques de morphinan et leur utilisation
PH12015502118A1 (en) Pyridin-4-yl derivatives
TN2016000556A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
CA2891755C (en) Substituted pyrido-piperazinone derivatives as gamma secretase modulators
MX364400B (es) Compuestos de tetraciclina.
MX360699B (es) Derivados de espiro [2.4] heptano puenteado substituidos por piperazina, utilizados como agonistas del receptor alx.
JOP20200030A1 (ar) مركب خماسي الحلقة
MX2015017541A (es) Derivados de espiro [2.4] heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
PH12015501056A1 (en) 2-pyridone compound
WO2019022235A9 (ja) 円形脱毛症の治療剤又は予防剤
IN2013MU03565A (es)

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: IDORSIA PHARMACEUTICALS LTD

FG Grant or registration